PM-8002 is under clinical development by Biotheus and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PM-8002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PM-8002 overview
PM-8002 is under development for the treatment of solid tumors, neuroendocrine tumors, such as small cell lung cancer, non-small cell lung cancer, hepatocellular carcinoma, malignant pleural mesothelioma, hormone receptor positive and/or HER2-positive breast cancer, triple-negative breast cancer (TNBC), metastatic hepatocellular carcinoma, platinum-resistant ovarian cancer, cervical cancer and renal cell carcinoma. The therapeutic candidate is a bi-specific monoclonal antibody. It is administered through intravenous and intravenous drip route. It acts by targeting PDL1 and VEGF A.
Biotheus overview
Biotheus is a clinical-stage biotech company that discovers, develops and delivers novel antibodies for oncology and inflammatory disease treatment. The company’s pipeline products include PM8002, PM8001, PM1015, PM1086, PM1003, PM1009, PM1022, PM1032, PM1130, PM1080, PM1092 and multiple ADCS. The company’s PM8002 is a next-generation PD-(L)1-based bispecific that blocks the PD-L1 and VEGF pathways and PM1009 is a next-generation checkpoint inhibitor to the PVR-TIGIT axis by inhibiting two non-redundant checkpoints TIGIT and PVRIG that targets tumors. The company operates through its subsidiaries in China and Hong Kong. Biotheus is headquartered in Zhuhai, Guangdong, China.
For a complete picture of PM-8002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
